InMed Pharmaceuticals Files Provisional Patent for Compositions Treating Eye Diseases

Vancouver, BC - May 12, 2015 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (CSE: IN; OTCQB: IMLFF), announced today that it has filed a provisional patent application with the United States Patent and Trademark Office ("USPTO") relating to the treatment of eye diseases.

Dr. Sazzad Hossain, CSO of InMed, commented, "We are pleased that our R & D efforts have culminated in the filing of a patent application within this large area of unmet medical needs. We have continued to build our expertise in the ocular disease area and believe the application that we have filed with the USPTO allows the Company to pursue a strategic IP strategy around the ocular therapy space including Glaucoma and other ocular diseases."

Mr. Craig Schneider, CEO of InMed, commented, "The filing of this patent application supplements our existing intellectual property portfolio and we plan to continue to file additional patent applications covering our technologies and novel therapies that will drive our long-term shareholder value."

A provisional patent application is a legal document which establishes an early priority date for the benefit of claiming "first to file" status against other companies or individuals that may want to file for a patent with similar claims after the filing date of our provisional application. 

About InMed
InMed is a clinical stage biopharmaceutical company that specializes in developing cannabis-based therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary platform technology, product pipeline, and accelerated development pathway are the fundamental value drivers of the Company. 

ON BEHALF OF THE BOARD

InMed Pharmaceuticals Inc.
Craig Schneider 
President and Chief Executive Officer
Tel: 604.669.7207
Fax: 604.683.2506
info@inmedpharma.com / www.inmedpharma.com

CONTACTS:

Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (Investors)
jdrumm@tiberend.com
212-375-2664

Amy Wheeler (Media)
awheeler@tiberend.com
646-362-5750

Forward-Looking Information

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about approval of a provisional patent application from the USPTO relating to the treatment of eye diseases; using the provisional patent application to pursue a strategic and broad business strategy to legally market and sell ocular therapy products; the plan to continue to file additional patent applications covering InMed's technologies and novel therapies that will drive long-term shareholder value; and the fundamental value drivers of the company. With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: the approval of the provisional patent application by the USPTO; the approval of additional patent applications; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: the USPTO may not approve the provisional patent application, or any future patent applications; InMed's proprietary platform technology, product pipeline and accelerated development pathway may not return their expected level of value; and economic or market conditions may worsen.

A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed's continuous disclosure filings with Canadian securities regulatory authorities at www.sedar.com. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.